The Association of Mitochondrial Copy Number With Sarcopenia in Adult Survivors of Childhood Cancer.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
02 11 2021
02 11 2021
Historique:
received:
18
11
2020
revised:
07
04
2021
accepted:
14
04
2021
pubmed:
20
4
2021
medline:
25
2
2022
entrez:
19
4
2021
Statut:
ppublish
Résumé
Adult childhood cancer survivors are at risk for frailty, including low muscle mass and weakness (sarcopenia). Using peripheral blood mitochondrial DNA copy number (mtDNAcn) as a proxy for functional mitochondria, this study describes cross-sectional associations between mtDNAcn and sarcopenia among survivors. Among 1762 adult childhood cancer survivors (51.6% male; median age = 29.4 years, interquartile range [IQR] = 23.3-36.8), with a median of 20.6 years from diagnosis (IQR = 15.2-28.2), mtDNAcn estimates were derived from whole-genome sequencing. A subset was validated by quantitative polymerase chain reaction and evaluated cross-sectionally using multivariable logistic regression for their association with sarcopenia, defined by race-, age-, and sex-specific low lean muscle mass or weak grip strength. All statistical tests were 2-sided. The prevalence of sarcopenia was 27.0%, higher among female than male survivors (31.5% vs 22.9%; P < .001) and associated with age at diagnosis; 51.7% of survivors with sarcopenia were diagnosed ages 4-13 years (P = .01). Sarcopenia was most prevalent (39.0%) among central nervous system tumor survivors. Cranial radiation (odds ratio [OR] = 1.84, 95% confidence interval [CI] = 1.32 to 2.59) and alkylating agents (OR = 1.34, 95% CI = 1.04 to 1.72) increased, whereas glucocorticoids decreased odds (OR = 0.72, 95% CI = 0.56 to 0.93) of sarcopenia. mtDNAcn decreased with age (β = -0.81, P = .002) and was higher among female survivors (β = 9.23, P = .01) and among survivors with a C allele at mt.204 (β = -17.9, P = .02). In adjusted models, every standard deviation decrease in mtDNAcn increased the odds of sarcopenia 20% (OR = 1.20, 95% CI = 1.07 to 1.34). A growing body of evidence supports peripheral blood mtDNAcn as a biomarker for adverse health outcomes; however, this study is the first to report an association between mtDNAcn and sarcopenia among childhood cancer survivors.
Sections du résumé
BACKGROUND
Adult childhood cancer survivors are at risk for frailty, including low muscle mass and weakness (sarcopenia). Using peripheral blood mitochondrial DNA copy number (mtDNAcn) as a proxy for functional mitochondria, this study describes cross-sectional associations between mtDNAcn and sarcopenia among survivors.
METHODS
Among 1762 adult childhood cancer survivors (51.6% male; median age = 29.4 years, interquartile range [IQR] = 23.3-36.8), with a median of 20.6 years from diagnosis (IQR = 15.2-28.2), mtDNAcn estimates were derived from whole-genome sequencing. A subset was validated by quantitative polymerase chain reaction and evaluated cross-sectionally using multivariable logistic regression for their association with sarcopenia, defined by race-, age-, and sex-specific low lean muscle mass or weak grip strength. All statistical tests were 2-sided.
RESULTS
The prevalence of sarcopenia was 27.0%, higher among female than male survivors (31.5% vs 22.9%; P < .001) and associated with age at diagnosis; 51.7% of survivors with sarcopenia were diagnosed ages 4-13 years (P = .01). Sarcopenia was most prevalent (39.0%) among central nervous system tumor survivors. Cranial radiation (odds ratio [OR] = 1.84, 95% confidence interval [CI] = 1.32 to 2.59) and alkylating agents (OR = 1.34, 95% CI = 1.04 to 1.72) increased, whereas glucocorticoids decreased odds (OR = 0.72, 95% CI = 0.56 to 0.93) of sarcopenia. mtDNAcn decreased with age (β = -0.81, P = .002) and was higher among female survivors (β = 9.23, P = .01) and among survivors with a C allele at mt.204 (β = -17.9, P = .02). In adjusted models, every standard deviation decrease in mtDNAcn increased the odds of sarcopenia 20% (OR = 1.20, 95% CI = 1.07 to 1.34).
CONCLUSIONS
A growing body of evidence supports peripheral blood mtDNAcn as a biomarker for adverse health outcomes; however, this study is the first to report an association between mtDNAcn and sarcopenia among childhood cancer survivors.
Identifiants
pubmed: 33871611
pii: 6237907
doi: 10.1093/jnci/djab084
pmc: PMC8562958
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1570-1580Subventions
Organisme : NCI NIH HHS
ID : P30 CA021765
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA174851
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM132231
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA195547
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
J Gerontol A Biol Sci Med Sci. 2014 May;69(5):584-90
pubmed: 24737561
Cell. 1998 Mar 20;92(6):829-39
pubmed: 9529258
Osteoporos Sarcopenia. 2015 Sep 1;1(1):39-45
pubmed: 26557727
Hum Mol Genet. 2013 Oct 1;22(19):3976-86
pubmed: 23760083
Hum Genet. 2014 Sep;133(9):1149-59
pubmed: 24902542
PLoS One. 2010 Jun 10;5(6):e11069
pubmed: 20548781
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Cell Metab. 2005 Jun;1(6):361-70
pubmed: 16054085
Cell. 2008 Jul 11;134(1):112-23
pubmed: 18614015
Med Sci Sports Exerc. 2019 Nov;51(11):2375-2390
pubmed: 31626055
Cancer Chemother Pharmacol. 2016 Oct;78(4):673-83
pubmed: 27167634
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
J Clin Oncol. 2015 Feb 10;33(5):479-91
pubmed: 25547510
Int J Radiat Biol. 2007 Jul;83(7):433-42
pubmed: 17538793
Pediatr Blood Cancer. 2011 May;56(5):825-36
pubmed: 21370418
Cancer. 2015 May 15;121(10):1540-7
pubmed: 25529481
Adv Exp Med Biol. 2017;982:347-358
pubmed: 28551797
Int J Biol Sci. 2017 Sep 5;13(9):1152-1162
pubmed: 29104506
Front Pharmacol. 2013 Apr 19;4:49
pubmed: 23626576
Blood. 2015 Jan 1;125(1):162-74
pubmed: 25411424
PLoS Genet. 2015 Jul 14;11(7):e1005306
pubmed: 26172475
Nature. 2012 Nov 15;491(7424):374-83
pubmed: 23151580
Mol Aspects Med. 2016 Aug;50:109-17
pubmed: 26921790
Pediatr Rehabil. 2006 Jul-Sep;9(3):267-74
pubmed: 17050404
Mitochondrion. 2015 Jan;20:13-21
pubmed: 25446395
Cancer. 2005 Apr 15;103(8):1730-9
pubmed: 15761876
J Bone Miner Res. 2018 Jul;33(7):1209-1218
pubmed: 29502340
J Clin Oncol. 2013 Dec 20;31(36):4496-503
pubmed: 24248696
J Radiat Res. 2018 Apr 1;59(suppl_2):ii114-ii120
pubmed: 29281054
Arch Phys Med Rehabil. 1985 Feb;66(2):69-74
pubmed: 3970660
Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16260-5
pubmed: 17053067
Neurochem Int. 2005 Feb;46(3):243-52
pubmed: 15670641
J Gerontol A Biol Sci Med Sci. 2006 Jun;61(6):534-40
pubmed: 16799133
Mol Pharmacol. 2019 Oct;96(4):408-417
pubmed: 31391291
Pediatr Blood Cancer. 2007 Dec;49(7):975-81
pubmed: 17091482
J Gerontol A Biol Sci Med Sci. 2004 Mar;59(3):255-63
pubmed: 15031310
Sci Rep. 2015 Mar 03;5:8717
pubmed: 25732599
PLoS One. 2017 Jul 10;12(7):e0181086
pubmed: 28700655
Int J Radiat Biol. 2018 Mar;94(3):282-288
pubmed: 29256737
Curr Pediatr Rev. 2014;10(4):249-62
pubmed: 25403639
Mol Interv. 2007 Jun;7(3):147-56
pubmed: 17609521
J Pers Soc Psychol. 1986 Dec;51(6):1173-82
pubmed: 3806354
Muscle Nerve. 1992 Mar;15(3):404-9
pubmed: 1557091
BMC Med Genet. 2020 Feb 24;21(1):40
pubmed: 32093658
Curr Protoc Hum Genet. 2011 Jan;Chapter 19:Unit 19.7.
pubmed: 21234878
PLoS One. 2011;6(12):e27811
pubmed: 22174747
N Engl J Med. 2006 Jan 12;354(2):166-78
pubmed: 16407512
Mol Cell Biol. 2013 Jan;33(2):194-212
pubmed: 23109432
J Neurol. 2002 Aug;249(8):1004-9
pubmed: 12195445
Cold Spring Harb Perspect Biol. 2012 Feb 01;4(2):
pubmed: 22300977
J Mol Med (Berl). 2015 Feb;93(2):177-186
pubmed: 25471480
Trends Cell Biol. 2005 Dec;15(12):666-73
pubmed: 16243526
Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5618-23
pubmed: 15800038
FEBS Lett. 2004 Jul 30;571(1-3):227-32
pubmed: 15280047
J Physiol. 2000 Jul 1;526 Pt 1:203-10
pubmed: 10878112
PLoS One. 2010 Jul 07;5(7):e11468
pubmed: 20628647
PLoS One. 2020 Jan 31;15(1):e0228166
pubmed: 32004343
Nat Rev Genet. 2005 May;6(5):389-402
pubmed: 15861210
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
J Physiol. 2012 Dec 1;590(23):5935-6
pubmed: 23204102
J Genet Genomics. 2009 Mar;36(3):125-31
pubmed: 19302968
Pediatr Blood Cancer. 2013 May;60(5):856-64
pubmed: 23024097
J Mol Cell Cardiol. 2012 Jun;52(6):1213-25
pubmed: 22465037
Science. 2005 Jul 15;309(5733):481-4
pubmed: 16020738
PLoS One. 2009 Sep 15;4(9):e7038
pubmed: 19753111
PLoS One. 2017 Jul 13;12(7):e0181036
pubmed: 28704533
J Physiol. 2016 Aug 15;594(16):4499-512
pubmed: 26921061
Annu Rev Genomics Hum Genet. 2010;11:25-44
pubmed: 20690818
Nat Commun. 2017 Jul 19;8(1):80
pubmed: 28724990
Phys Ther. 2016 Jul;96(7):1029-38
pubmed: 26893509
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Chin Med J (Engl). 2017 Oct 20;130(20):2435-2440
pubmed: 29052564
Nat Genet. 1999 Oct;23(2):147
pubmed: 10508508
PLoS Genet. 2014 Sep 18;10(9):e1004620
pubmed: 25232829
Front Physiol. 2015 Feb 03;6:12
pubmed: 25691871
Hum Mutat. 2013 Sep;34(9):1189-94
pubmed: 23696374
Biochem Biophys Res Commun. 2016 Apr 29;473(2):578-85
pubmed: 27033601
Nature. 2016 May 02;533(7603):416-9
pubmed: 27135930
J Hand Surg Am. 1985 Sep;10(5):694-7
pubmed: 4045150
J Clin Oncol. 2005 Apr 20;23(12):2629-36
pubmed: 15837978
J Pathol. 2005 Dec;207(4):436-44
pubmed: 16278810
Front Physiol. 2016 Jan 12;6:422
pubmed: 26793123
PLoS Genet. 2016 Mar 15;12(3):e1005939
pubmed: 26978189